Evidence map›Paper›PMID 30651786›Full record

ArticleExperimental and therapeutic medicine2019

microRNA-200a functions as a tumor suppressor by targeting FOXA1 in glioma.

Xiaofeng Chen, Kun Liu, Ping Yang, Weiping Kuang, Hongxing Huang, Ewen Tu, Bo Li, Yong Zhu, Bin Zhou, Lin Yan

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Potential Five-MicroRNA Signature Model for the Prediction of Prognosis in Patients with Wilms Tumor.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Xiaofeng ChenDepartment of Neurosurgery, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China.
Kun LiuDepartment of Neurosurgery, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China.
Ping YangDepartment of Psychiatry, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China.
Weiping KuangDepartment of Neurosurgery, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China.
Hongxing HuangDepartment of Neurosurgery, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China.
Ewen TuDepartment of Neurology, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China.
Bo LiDepartment of Neurosurgery, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China.
Yong ZhuDepartment of Neurosurgery, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China.
Bin ZhouDepartment of Neurosurgery, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China.
Lin YanDepartment of Neurosurgery, Brain Hospital of Hunan Province, Changsha, Hunan 410007, P.R. China.
Hunan Institute of Mental Health · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

microRNAs (miRs) serve primary roles in certain human malignancies; however, the detailed regulatory mechanism of miR-200a in glioma progression is yet to be fully elucidated. The current study aimed to assess the expression of miR-200a in glioma as well as the regulatory mechanism of miR-200a in glioma cell proliferation, survival and invasion. RT-qPCR and western blotting were performed to examine mRNA and protein expression. An MTT assay, an EdU incorporation cell proliferation assay and a transwell assay were utilized to assess cell survival, proliferation and invasion. The results indicated that the miR-200a levels were significantly reduced in glioma tissues compared with normal brain tissues. Levels were also downregulated in glioma cell lines when compared with those in normal human astrocyte cells. Furthermore, low miR-200a expression was associated with advanced progression of glioma. The overexpression of miR-200a inhibited glioma cell proliferation, survival and invasion. Results also identified that FOXA1 was a target gene of miR-200a in glioma cells and that the increased expression of FOXA1 was negatively correlated to the decreased expression of miR-200a in glioma tissues. Furthermore, FOXA1 expression was negatively mediated by miR-200a in glioma cells and the overexpression of FOXA1 eliminated the inhibitory effects of miR-200a on the survival, proliferation and invasion of glioma cells. In conclusion, the current study demonstrated that miR-200a functions acts as a tumor suppressor in glioma by directly targeting FOXA1 and may thus be a potential candidate for the treatment of glioma.

Indexed as

forkhead box A1gliomamicroRNA-200atumor suppressor

Identifiers

PMID30651786
PMCPMC6307448
OpenAlexW2898923110

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.